Moreover, administering GS967 -a selective blocker of Nav1.6- reduces spontaneous seizures and prolongs the survival of heterozygous mice of N1768D Scn8a and Scn1a+/− Dravet syndrome [80]. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.